Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults
NCT04584710Phase 2Active, not recruiting
- Sponsor
- resTORbio
- Start
- Oct 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dactolisib in coronavirus disease 2019 (COVID-19), sponsored by resTORbio. Started Oct 2020; status: active, not recruiting.
02
Drugs
dactolisib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04584710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584710.